15:30:44 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
RaySearch Laboratories är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av mjukvarulösningar för sjukvårdsindustrin. Särskilt område där bolagets produkter används är inom cancervården. Bolagets produkter vidaresäljs som dosplanerings- respektive informationssystem. Olika funktioner inkluderar maskininlärning, beräkningshastighet, automatiserad planering, virtuell simulering, adaptiv terapi och digitala arbetsflöden. Produkterna används av ett flertal kliniker.

Kalender

2022-05-25 Årsstämma 2022
2022-05-18 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning RAY B 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning RAY B 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-22 Ordinarie utdelning RAY B 0.00 SEK
2019-05-21 Årsstämma 2019
2019-05-09 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning RAY B 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning RAY B 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Ordinarie utdelning RAY B 0.25 SEK
2016-05-17 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning RAY B 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-08 Kvartalsrapport 2015-Q1
2015-02-12 Bokslutskommuniké 2014
2014-11-27 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning RAY B 0.00 SEK
2014-05-27 Årsstämma 2014
2014-05-16 Kvartalsrapport 2014-Q1
2014-02-13 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning RAY B 0.00 SEK
2013-05-22 Årsstämma 2013
2013-05-16 Kvartalsrapport 2013-Q1
2013-02-14 Bokslutskommuniké 2012
2012-11-16 Kvartalsrapport 2012-Q3
2012-08-28 Kvartalsrapport 2012-Q2
2012-05-31 Ordinarie utdelning RAY B 0.00 SEK
2012-05-30 Årsstämma 2012
2012-05-23 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-11-24 Kvartalsrapport 2011-Q3
2011-05-26 Ordinarie utdelning RAY B 0.50 SEK
2011-05-25 Årsstämma 2011
2011-05-04 Kvartalsrapport 2011-Q1
2011-02-18 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-27 Kvartalsrapport 2010-Q2
2010-05-26 Ordinarie utdelning RAY B 0.50 SEK
2010-05-25 Årsstämma 2010
2010-05-11 Kvartalsrapport 2010-Q1
2009-11-20 Kvartalsrapport 2009-Q3
2009-08-27 Kvartalsrapport 2009-Q2
2009-05-27 Ordinarie utdelning RAY B 0.00 SEK
2009-05-26 Årsstämma 1
2009-05-15 Kvartalsrapport 2009-Q1
2008-06-25 Split RAY B 1:3
2003-06-10 Split RAY B 20:1
2021-05-05 07:45:00

"In the first quarter of 2021, net sales declined 22 percent due to lower license sales. Recurring support revenue rose 7 percent and accounts for 38 percent (28) of net sales. Operating profit totaled SEK 12 M (52) and cash flow was SEK 33 M (-4)", says Johan Löf, CEO of RaySearch.
 

FIRST QUARTER (JANUARY-MARCH 2021)
  • Order intake SEK 145.1 M (300.0)
  • Net sales SEK 162.1 M (208.9)
  • Operating profit SEK 12.3 M (51.6)
  • Profit after tax SEK 7.1 M (40.5)
  • Earnings per share before/after dilution SEK 0.21 (1.18)
  • Cash flow SEK 32.8 M (-4.2)
  • Order backlog SEK 1,207.1 M (1,281.5) at the end of the period
SIGNIFICANT EVENTS DURING THE FIRST QUARTER
  • The RayStation®* treatment planning system was sold to more leading cancer centers, including Legacy Cancer Institute in the US, the University Hospital in Krakow, Poland, Osaka City University Hospital and Kumamoto University Hospital in Japan. In addition, Inova Schar Cancer Institute in the US and Radiumhospitalet at Oslo University Hospital in Norway expanded their existing RayStation installations.
  • In March, the Parent Company issued a short-term loan of SEK 200,000 to Vinstandelsstiftelsen RayFoundation on commercial terms.
  • A wholly owned subsidiary has been established in Australia.
UPDATE REGARDING COVID-19
  • The COVID-19 pandemic with temporary reprioritisations in healthcare had a negative impact on sales in the first quarter. The market situation is gradually improving in line with the vaccine rollout and the recovery is expected to continue. At the same time, coronavirus cases are rising in some regions and it is unclear how long it will take before the vaccination program has an effect. RaySearch therefore expects that the negative effects of the COVID-19 pandemic on the company's sales and earnings will continue for some months to come, mainly because orders may be delayed, but that the pandemic's effects on sales and earnings are expected to gradually diminish in 2021.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
  • In March 2021, RaySearch breached an EBITDA-based covenant in the company's credit facility agreement with Skandinaviska Enskilda Banken (publ) (SEB) with a credit limit of SEK 350 M, of which SEK 50 M was utilized. In April, SEB subsequently demanded repayment of the utilized SEK 50 M. However, the credit facility will be available for drawing as soon as the company once again meets all covenants contained in the agreement.
  • A sales agent agreement has been signed with Canon Medical Systems USA, Inc., enabling RaySearch's salesforce in North America to promote Canon Medical's Aquilion Lare Bore CT and Celesteion PET/CT products.

 

TELECONFERENCE IN CONJUNCTION WITH THE INTERIM REPORT

CEO Johan Löf and CFO Peter Thysell will present RaySearch's interim report for January-March 2021 at a teleconference to be held in English on Wednesday, May 5, 2021 at 4:00-4:30 p.m. CEST.

For login details to the teleconference (ID: 5061876), please register on:
http://emea.directeventreg.com/registration/5061876

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

Johan Löf, President and CEO                   Tel: +46 8 510 530 00              E-mail: johan.lof@raysearchlabs.com
Peter Thysell, CFO                                     Tel: +46 70 661 05 59              E-mail: peter.thysell@raysearchlabs.com

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 5, 2021 at 7:45 a.m. CEST.
 

ABOUT RAYSEARCH

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare*. In December 2020, the company also launched a new treatment control system, RayCommand*, as well as the data anlytics system, RayIntelligence*. RaySearch's software is currently used by more than 2,600 cancer centers in more than 65 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed for trading on Nasdaq Stockholm since 2003.
More information about RaySearch is available at www.raysearchlabs.com.

[*] Marketing clearance is required in some markets.